Harmony Biosciences Holdings (HRMY) Cash from Investing Activities (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Cash from Investing Activities data on file, last reported at -$183.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 7875.02% year-over-year to -$183.6 million; the trailing twelve-month figure through Mar 2026 stood at -$225.7 million (down 282.88% YoY), and the FY2025 full-year result was -$39.6 million, up 41.25% from the prior year.
• Cash from Investing Activities retreated to -$183.6 million in Q1 2026, from -$17.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $2.4 million in Q1 2025 to a low of -$183.6 million in Q1 2026.
• A 5-year average of -$28.2 million and a median of -$17.6 million in 2025 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities slumped 34787.1% in 2022 and soared 191.64% in 2024, its largest moves.
• Tracing HRMY's Cash from Investing Activities over 5 years: stood at -$46.9 million in 2022, then grew by 23.09% to -$36.1 million in 2023, then surged by 80.07% to -$7.2 million in 2024, then slumped by 145.35% to -$17.6 million in 2025, then plunged by 941.49% to -$183.6 million in 2026.
• Business Quant data shows HRMY's Cash from Investing Activities at -$183.6 million in Q1 2026, -$17.6 million in Q4 2025, and -$4.8 million in Q3 2025.